Sagaliam Acquisition Corp Launches Improved IPF Formula with Vitamin C in Pill and Lozenge Form and Addition of New Slimming Neutraceutical
Sagaliam Acquisition Corp (SAGA) announced the launch of a new IPF formula, IPF Immune+ with Vit C, developed by Virogentics, Inc., a subsidiary of SAGA, and a Bulgarian product development team. The product combines Vitamin C with an existing patented compound and will be available in pill and lozenge form. Additionally, a new slimming formula will be added to the VIRO nutraceutical product line. CEO Barry Kostiner expressed enthusiasm for the consumer approval of the IPF nutraceutical and highlighted future collaborations with Enzolytics for expanding the company's wellness product portfolio. SAGA's partnership with Dr. Lachezar Ivanov is expected to result in the development of brain detox and liver detox nutraceuticals in the American market, along with the latest IPF immune formulation with Vitamin C.
Launch of a new IPF formula, IPF Immune+ with Vit C, providing a more effective delivery method for users.
Development of a new slimming formula to expand the VIRO nutraceutical product line.
Strong consumer approval of the IPF nutraceutical product.
Partnership with Dr. Lachezar Ivanov leading to a pipeline of significant consumer nutraceutical products.
- None.
BAYTOWN, TX / ACCESSWIRE / May 1, 2024 / Sagaliam Acquisition Corp ("SAGA", the "Company") (NASDAQ:SAGA) announced today that Virogentics, Inc., a wholly owned subsidiary of SAGA ("VIRO"), and the Bulgarian product development team, headed by Dr. Lachezar Ivanov and Harry Zhabilov, CSO, have developed a new IPF formula which combines a Vitamin C component with the existing patented compound. This product will be marketed as IPF Immune+ with Vit C. In addition, this new product will be available in both pill and lozenge form providing convenience and a more effective delivery for the users. The team has also begun production of a new slimming formula which will be added to the VIRO nutraceutical product line.
Barry Kostiner, the CEO of Sagaliam, commented, "Our IPF nutraceutical has received strong consumer approval, and we look forward to ramping up our marketing efforts, in parallel with our other nutraceutical products. We are grateful for our relationship with Enzolytics and look forward to participating in its development of Sales, Marketing and Distribution infrastructure to service our expanded portfolio of consumer wellness products. Sagaliam's partnership with Dr. Lachezar Ivanov has resulted in a pipeline of significant consumer nutraceutical products. In addition to IPF Immune, we will be working with Dr. Ivanov to deliver brain detox and liver detox nutraceuticals to the American market, as well as our latest development, IPF immune formulated in tablets and lozenges with Vitamin C."
About Sagaliam Acquisition Corp.
We are a blank check company incorporated under the laws of the State of Delaware on March 31, 2021 for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses or entities. Sagaliam intends to continue to pursue the consummation of a business combination with an appropriate target.
Virogentics, a subsidiary of Sagaliam, is advancing multiple therapeutics targeting numerous infectious diseases. One patented and clinically tested compound, ITV-1 (Immune Therapeutic Vaccine-1), is a suspension of Inactivated Pepsin Fraction (IPF), covered by U.S. Patent Nos. 8,066,982 and 7,479,538. Studies have shown it to be effective in treating HIV/AIDS. ITV-1 has also been shown to modulate the immune system.
Forward Looking Statements
The disclosure herein includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook," and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding projections, estimates and forecasts of revenue and other financial and performance metrics and projections of market opportunity and expectations, Company's ability to enter into a definitive business combination agreement and Company's ability to obtain the financing necessary to consummate the potential business combination transaction. These statements are based on various assumptions and on the current expectations of Company's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Company. These forward-looking statements are subject to a number of risks and uncertainties, including: Company's ability to enter into a definitive agreement with respect to the proposed business combination or consummate a transaction; the risk that the approval of the stockholders of Company for the potential transaction is not obtained; failure to realize the anticipated benefits of the potential transaction, including as a result of a delay in consummating the potential transaction or difficulty in integrating the businesses of Company; the amount of redemption requests made by Company's stockholders and the amount of funds remaining in Company's trust account after satisfaction of such requests; those factors discussed in Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 under the heading "Risk Factors," and other documents of Company filed, or to be filed, with the SEC. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Company presently does not know or that Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Company's expectations, plans or forecasts of future events and views as of the date hereof. Company anticipates that subsequent events and developments will cause Company's assessments to change. However, while Company may elect to update these forward-looking statements at some point in the future, Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Company's assessments as of any date subsequent to the date of this disclosure statement. Accordingly, undue reliance should not be placed upon the forward-looking statements.
CONTACT INFORMATION
Sagaliam Acquisition Corp
Barry Kostiner, Chief Executive Officer
3002 Royal Palm
Baytown, Texas 77523
Tel: (845) 925-4597
SOURCE: Sagaliam Acquisition Corp.
View the original press release on accesswire.com
FAQ
What is the new IPF formula launched by Sagaliam Acquisition Corp?
Who led the Bulgarian product development team in creating the new IPF formula?
What is the purpose of the new slimming formula being added to the VIRO nutraceutical product line?
What are some future product developments planned by Sagaliam Acquisition Corp in collaboration with Dr. Lachezar Ivanov?
